Search Result

Results for "

Type I kinase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AMPK (1) Anaplastic lymphoma kinase (ALK) (3) Apoptosis (12) Autophagy (3) Bcr-Abl (7) c-Kit (4) c-Met/HGFR (1) c-Myc (1) Calcium Channel (2) CDK (2) Cholinesterase (ChE) (2) DGK (1) Drug Metabolite (1) EGFR (3) ERK (2) FLT3 (3) IFNAR (3) IMPDH (1) Interleukin Related (2) Isotope-Labeled Compounds (2) JAK (4) Mitochondrial Metabolism (1) mRNA (1) mTOR (1) Organoid (4) p38 MAPK (3) PACAP Receptor (2) PDGFR (3) Phosphatase (2) PI4P5K (1) PKA (6) PKC (3) PKG (3) Reactive Oxygen Species (ROS) (3) Reference Standards (5) SARS-CoV (1) Ser/Thr Protease (1) Src (2) STAT (2) Syk (1) TAM Receptor (1) TGF-beta/Smad (2) TGF-β Receptor (17) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (45) Cardiovascular Disease (1) Infection (3) Inflammation/Immunology (8) Metabolic Disease (8) Neurological Disease (8)
Oligonucleotides:	Interferon & Receptors (1) mRNA (1) Antisense Oligonucleotides (2)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Targets Recommended: C-type Lectin-like Receptors (CTLRs) PCSK9 Scavenger Receptor Class B type I (SR-BI）

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10432

A 83-01 Maximum Cited Publications 129 Publications Verification	Organoid TGF-β Receptor	Cancer
A 83-01 is a potent inhibitor of TGF-β type I receptor ALK5 kinase, type I nodal receptor ALK4 and type I nodal receptor ALK7, with IC₅₀s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7, respectively .

HY-13012

RepSox 20+ Cited Publications E-616452; SJN 2511	Organoid TGF-β Receptor	Metabolic Disease
RepSox (E-616452) is a potent and selective *transforming growth factor-beta receptor I/activin like kinase* 5 (TGF-β-RI/ALK5) inhibitor. RepSox inhibits ALK5 autophosphorylation with an IC₅₀** value of 4 nM. RepSox can be used for the research of obesity and associated metabolic diseases such as type 2 diabetes .

HY-13226

Galunisertib 65+ Cited Publications LY2157299	TGF-β Receptor	Cancer
Galunisertib (LY2157299) is an oral and selective TGF-β receptor type I (TGF-βRI) kinase inhibitor with an IC₅₀ of 56 nM.

HY-117287

Deucravacitinib 30+ Cited Publications BMS-986165	JAK STAT Interleukin Related IFNAR	Inflammation/Immunology
Deucravacitinib (BMS-986165) is an orally active allosteric inhibitor of tyrosine kinase 2 (TYK2), with an IC₅₀ of 0.2 nM and a K_i of 0.02 nM against the JH2 domain of TYK2, and it exhibits selectivity over other JAK subtypes and most of the kinome. Deucravacitinib blocks IL-23, IL-12, p-STAT1/3 and Type I IFN signaling, and inhibits Th17/Th1-mediated psoriasis inflammation . Deucravacitinib can be used in research related to moderate-to-severe plaque psoriasis, inflammatory bowel disease and systemic lupus erythematosus .

HY-P0221

PACAP (1-38), human, ovine, rat 5 Publications Verification Pituitary Adenylate Cyclase Activating Polypeptide 38	PACAP Receptor ERK EGFR Reactive Oxygen Species (ROS) Calcium Channel	Infection Neurological Disease
PACAP (1-38), human, ovine, rat is a PAC₁ receptor agonist. PACAP (1-38), human, ovine, rat binds to PACAP type I receptor, PACAP type II receptor VIP1, and PACAP type II receptor VIP2 with IC₅₀s of 4 nM, 2 nM, and 1 nM, respectively. PACAP (1-38), human, ovine, rat increases the α-secretase activity. PACAP (1-38), human, ovine, rat elevates cytosolic Ca ²⁺, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP (1-38), human, ovine, rat demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP (1-38), human, ovine, rat can be used for neurotrophic and neuroprotective research .

HY-10432A

A 83-01 sodium Maximum Cited Publications 129 Publications Verification	Organoid TGF-β Receptor	Cancer
A 83-01 sodium is a potent inhibitor of TGF-β type I receptor ALK5 kinase, ALK4 and ALK7, with IC₅₀s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7, respectively .

HY-145015

Tuspetinib HM43239	FLT3 Apoptosis	Cancer
Tuspetinib (HM43239) is an orally active and selective FLT3 inhibitor with IC₅₀s of 1.1 nM, 1.8 nM and 1.0 nM for FLT3 WT, FLT3 internal tandem duplication (ITD) and FLT3 D835Y kinases, respectively. Tuspetinib inhibits the kinase activity of FLT3 as a reversible type I inhibitor and modulates p-STAT5, p-ERK, SYK, JAK1/2, and TAK1. Tuspetinib inhibits the proliferation and induces the apoptosis of leukemic cells .

HY-16397

Phenformin 5+ Cited Publications Phenethylbiguanide	Mitochondrial Metabolism AMPK Apoptosis Autophagy mTOR	Neurological Disease Metabolic Disease Cancer
Phenformin (Phenethylbiguanide) is an orally active biguanide hypoglycemic agent. Phenformin inhibits mitochondrial respiratory chain complex I, leading to an increased AMP/ATP ratio, activation of AMPK, and subsequent inhibition of the mTOR pathway, thereby suppressing cell proliferation, inducing apoptosis and autophagy. Phenformin inhibits cancer stem cells (CSCs) and possesses potent antitumor potential .

HY-16712

LDN-214117 2 Publications Verification	TGF-β Receptor	Cancer
LDN-214117 is an orally active ALK2 inhibitor with well-tolerated and good brain penetration. LDN-214117 has a high selectivity and low cytotoxicity for ALK2 with an IC₅₀ value of 24 nM. LDN-214117 also is a specific bone morphogenetic proteins (BMPs) signaling inhibitor and has relatively selective inhibition for BMP6 with an IC₅₀ value of 100 nM. LDN-214117 can be used for the research of fibrodysplasia ossificans progressiva (FOP), diffuse intrinsic pontine glioma (DIPG) .

HY-108355

R59949 1 Publications Verification	PKC	Cancer
R59949 is a pan *diacylglycerol kinase* (DGK) inhibitor with an IC₅₀** of 300 nM. R59949 strongly inhibits the activity of type I DGK α and γ and moderately attenuates the activity of type II DGK θ and κ. R59949 activates protein kinase C (PKC) by enhancing the levels of the endogenous ligand diacyl glycerol .

HY-153268

Silevertinib 2 Publications Verification BDTX-1535; EGFR-IN-76	EGFR	Infection Neurological Disease Metabolic Disease Cancer
Silevertinib (BDTX-1535) is an irreversible, brain-penetrant, selective and orally active EGFR inhibitor with wild-type EGFR-sparing. Silevertinib targets key EGFR resistance mutations, including the kinase domain (C797S, L718Q, G724S, *S768I), extracellular domain (EGFRvIII, A289X*), and EGFR amplification. Silevertinib exerts anti-tumor activity with well tolerated in vivo. Silevertinib can be used for non-small cell lung cancer (NSCLC) and glioblastoma (GBM) research .

HY-18623

VI 16832	Syk Src	Cancer
VI 16832 is a broad spectrum **Type I kinase** inhibitor which can be used as an enrichment tool for the comparative expression analysis of protein kinases in different cancer cell lines.

HY-12293

LY2857785 4 Publications Verification	CDK Apoptosis	Cancer
LY2857785 is a type I reversible and competitive ATP kinase inhibitor against CDK9 (IC₅₀ 11 nM) and other transcription kinases CDK8 (IC₅₀ 16 nM), and CDK7 (IC₅₀ 246 nM).

HY-78349

A 77-01 2 Publications Verification	TGF-β Receptor	Cancer
A 77-01 is a potent inhibitor of transforming growth factor (TGF)-β type I receptor superfamily *activin-like kinase* ALK5 with an IC₅₀** of 25 nM .

HY-18758

IN-1130 1 Publications Verification	TGF-β Receptor	Inflammation/Immunology Cancer
IN-1130 is a highly selective *transforming growth factor-β type* I receptor kinase (ALK5) inhibitor with an IC₅₀ of 5.3 nM for ALK5-mediated Smad3 phosphorylation. IN-1130 inhibits ALK5 phosphorylation of casein (IC₅₀*=36 nM) and p38α mitogen-activated protein kinase* (IC₅₀=4.3 μM). IN-1130 suppresses renal fibrosis in obstructive nephropathy and blocks breast cancer lung metastasis .

HY-153701S

Envudeucitinibum Envudeucitinib; ESK-001	JAK Interleukin Related IFNAR Isotope-Labeled Compounds	Inflammation/Immunology
Envudeucitinibum (Envudeucitinib) is a highly selective, allosteric and orally active TYK2 inhibitor binding to the JH2 domain of TYK2. Envudeucitinibum has no off-target effects on other kinases (JAK1-3). Envudeucitinibum reduces signaling and production of proinflammatory cytokines including IL-12, IL-23, IL-17, and type I interferons (IFNs). Envudeucitinibum can be used for the research of plaque psoriasis, systemic lupus erythematosus (SLE), and other immune-mediated diseases .

HY-P10954

Link N peptide	p38 MAPK	Others
Link N peptide is a proteoglycan aggregates activator in the extracellular matrix. Link N peptide can selectively activate the p38 mitogen-activated protein kinase (MAPK) pathway to promote the expression of type I and II collagens in human intervertebral disc cells. Link N peptide is promising for research of intervertebral disc degeneration-related diseases .

HY-N4119

Neoeriocitrin	Phosphatase Cholinesterase (ChE) p38 MAPK Apoptosis Autophagy	Neurological Disease Metabolic Disease
Neoeriocitrin is a Naringin (HY-N0153) analogue found in Drynaria Rhizome. Neoeriocitrin induces cells proliferation, differentiation, up-regulates type I collagen, osteocalcin, and key osteogenic markers, and increases ALP activity. Neoeriocitrin increases expression of Runx2, COL I, OCN and Beclin1. Neoeriocitrin inhibits phosphorylation of P38 mitogen-activated protein kinase, reduces acetylcholinesterase (AChE) activity, and increases choline acetyltransferase (ChAT) activity. Neoeriocitrin reduces apoptosis and induces autophagy. Neoeriocitrin can be used for the researches of osteoporosis and Alzheimer's disease .

HY-162266

C3TD879	Ser/Thr Protease	Cancer
C3TD879 is a Type I kinase inhibitor that potently inhibits CITK catalytic activity (IC₅₀ = 12 nM). C3TD879 binds directly to full-length human CITK in cells (NanoBRET K_d < 10 nM). C3TD879 is a chemical probe suitable for interrogating the complex biology of CITK .

HY-132893

AZ14145845	TAM Receptor	Cancer
AZ14145845 is a highly selective type I1/2 dual Mer/Axl kinase inhibitor with in vivo efficacy.

HY-15814

HG-7-85-01	Bcr-Abl PDGFR c-Kit Src JAK Apoptosis	Cancer
HG-7-85-01 is a type II ATP competitive inhibitor of wild-type and gatekeeper mutations forms of Bcr-Abl, PDGFRα, Kit, and Src kinases. HG-7-85-01 inhibits T315I mutant Bcr-Abl kinase, KDR and RET with IC₅₀s of 3 nM, 20 nM and 30 nM, and is only weak or no inhibition of other kinases (IC₅₀>2 μM). HG-7-85-01 inhibits the cell proliferation, which is mediated by the induction of apoptosis, and inhibition of cell-cycle progression .

HY-149665

BMS-684 1 Publications Verification	DGK	Cancer
BMS-684 is a selective DGKα inhibitor with an IC₅₀ of 15 nM. BMS-684 inhibits DGKα kinase activity with >100-fold selectivity over the related DGK type I family members DGKβ and DGKγ. BMS-684 does not inhibit any of the other seven DGK isozymes .

HY-123450

S116836	Bcr-Abl Apoptosis PDGFR	Cancer
S116836, a potent, orally active BCR-ABL tyrosine kinase inhibitor, blocks both wild-type as well as T315I Bcr-Abl. S116836 arrests the cells in the G0/G1 phase of cell cycle, induces apoptosis, increases ROS production, and decreases GSH production in BaF3/WT and BaF3/T315I cells. S116836 also inhibits SRC, LYN, HCK, LCK and BLK, and receptor tyrosine kinases such as FLT3, TIE2, KIT, PDGFR-β. Antitumor activies . S116836 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-128437

TGFβ-IN-5 1 Publications Verification	TGF-β Receptor	Inflammation/Immunology
TGFβ-IN-5 is a type I transforming growth factor-β receptor (TGF-β R1) kinase inhibitor with an IC₅₀ value of 0.0485 μM. TGFβ-IN-5 reverses the effect of TGF-β-mediated cell activation on the expression of fibrosis-related genes. TGFβ-IN-5 can be used in the research of fibroproliferative diseases .

HY-10432R

A 83-01 (Standard)	Reference Standards TGF-β Receptor	Cancer
A 83-01 (Standard) is the analytical standard of A 83-01 (HY-10432). This product is intended for research and analytical applications. A 83-01 is a potent inhibitor of TGF-β type I receptor ALK5 kinase, type I nodal receptor ALK4 and type I nodal receptor ALK7, with IC₅₀s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7, respectively .

HY-163572

PIP5K1α-IN-1	PI4P5K	Cancer
PIP5K1α-IN-1 (Compound 3e) is an inhibitor for phosphatidylinositol 4-phosphate 5-kinase type I α (PIP5K1α) with an IC₅₀ of 0.46 μM .

HY-12083

PPY-A	Bcr-Abl	Cancer
PPY-A is a potent T315I mutant and wild-type Abl kinases inhibitor with IC₅₀s of 9 and 20 nM, respectively. PPY-A inhibits Ba?F3 cells transformed with wild-type Abl and Abl T315I mutantl with IC₅₀s of 390 and 180 nM, respectively. PPY-A can be used for the research of chronic myeloid leukemia (CML) .

HY-147342

β-Benzamide adenine dinucleotide	Drug Metabolite IMPDH	Cancer
β-Benzamide adenine dinucleotide is a biologically active metabolite of benzamide riboside. β-Benzamide adenine dinucleotide is a competitive inhibitor of human NAD kinase with a K_i value of 90 μM, and inhibits human IMPDH with IC₅₀ values of 0.787 μM and 0.884 μM for type I and type II, respectively. β-Benzamide adenine dinucleotide exhibits inhibitory activities against lactate dehydrogenase, glutamate dehydrogenase, and malate dehydrogenase. β-Benzamide adenine dinucleotide can be used for the study of chronic myelogenous leukemia .

HY-137108

Sp-8-pCPT-cGMPS	PKA PKG	Neurological Disease
Sp-8-pCPT-cGMPS is a potent cyclic guanosine monophosphate-gated channel agonist and a lipophilic activator of *protein kinase* G** (types I α, I β, and II) and *protein kinase* A** type II with excellent cell membrane permeability and phosphodiesterase stability. Sp-8-pCPT-cGMPS can be used to study the role of cGMP in neural plasticity and synaptic transmission .

HY-13012R

RepSox (Standard) E-616452 (Standard); SJN 2511 (Standard)	Organoid TGF-β Receptor Reference Standards	Metabolic Disease
RepSox (Standard) is the analytical standard of RepSox. This product is intended for research and analytical applications. RepSox (E-616452) is a potent and selective transforming growth factor-beta receptor I/activin like kinase 5 (TGF-β-RI/ALK5) inhibitor. RepSox inhibits ALK5 autophosphorylation with an IC50 value of 4 nM. RepSox can be used for the research of obesity and associated metabolic diseases such as type 2 diabetes .

HY-13226A

Galunisertib monohydrate	TGF-β Receptor	Cancer
Galunisertib monohydrate is an oral and selective TGF-β receptor type I (TGF-βRI) kinase inhibitor with an IC₅₀ of 56 nM.

HY-119370

CHMFL-ABL-121	Bcr-Abl Apoptosis	Cancer
CHMFL-ABL-121 is a highly potent type II ABL kinase inhibitor with IC₅₀s of 2 nM and 0.2 nM against purified inactive ABL wt and T315I kinase protein, respectively .

HY-10364

AP24163	Bcr-Abl	Cancer
AP24163 is a BCR-ABL kinase inhibitor. AP24163 inhibits wild-type (native) BCR-ABL and *BCR-ABL-T315I* with IC₅₀ values of 7 nM and 511 nM, respectively. AP24163 can be used in the research of chronic myeloid leukemia (CML) .

HY-13226R

Galunisertib (Standard) LY2157299 (Standard)	TGF-β Receptor Reference Standards	Cancer
Galunisertib (Standard) is the analytical standard of Galunisertib. This product is intended for research and analytical applications. Galunisertib (LY2157299) is an oral and selective TGF-β receptor type I (TGF-βRI) kinase inhibitor with an IC50 of 56 nM.

HY-145015A

Tuspetinib hydrate HM43239 hydrate	FLT3 Apoptosis	Cancer
Tuspetinib (HM43239) hydrate is an orally active and selective FLT3 inhibitor with IC₅₀s of 1.1 nM, 1.8 nM and 1.0 nM for FLT3 WT, FLT3 internal tandem duplication (ITD) and FLT3 D835Y kinases, respectively. Tuspetinib hydrate inhibits the kinase activity of FLT3 as a reversible type I inhibitor and modulates p-STAT5, p-ERK, SYK, JAK1/2, and TAK1. Tuspetinib hydrate inhibits the proliferation and induces the apoptosis of leukemic cells .

HY-145015B

Tuspetinib dihydrochloride HM43239 dihydrochloride	FLT3 Apoptosis	Cancer
Tuspetinib (HM43239) dihydrochloride is an orally active and selective FLT3 inhibitor with IC₅₀s of 1.1 nM, 1.8 nM and 1.0 nM for FLT3 WT, FLT3 internal tandem duplication (ITD) and FLT3 D835Y kinases, respectively. Tuspetinib dihydrochloride inhibits the kinase activity of FLT3 as a reversible type I inhibitor and modulates p-STAT5, p-ERK, SYK, JAK1/2, and TAK1. Tuspetinib dihydrochloride inhibits the proliferation and induces the apoptosis of leukemic cells .

HY-W684904

LY550410	TGF-β Receptor	Cancer
LY550410 is a small-molecule ATP-competitive inhibitor against **type I TGF-β receptor kinase*, which contains heteroaryl rings for potent binding to the kinase*-domain active site. LY550410 modulates TGF-β signalling, thereby regulates gene expression and ultimately cell growth. LY550410 is promising for research of cancers .

HY-137530

8-MA-cAMP 8-Methylamino-cAMP	PKA	Others
8-MA-cAMP (8-Methylamino-cAMP) is a cyclic AMP analog that acts as a site-selective PKA agonist with similar affinity for the B site of type I and type II protein kinase A. 8-MA-cAMP is used in conjunction with priming analogs that show site A preference, such as 8-piperidinyl cAMP, to achieve selective stimulation of type I .

HY-E70737

KIT T670I Recombinant Human Active Protein Kinase	c-Kit	Cancer
KIT (CD117) is an important cell surface marker used to identify certain types of hematopoietic(blood) progenitors in the bone marrow. KIT is a cytokine receptor expressed on the surface of hematopoietic stem cells as well as other cell types. Altered forms of this receptor may be associated with some types of cancer. KIT T670I is a mutant of KIT. KIT T670I Recombinant Human Active Protein Kinase is a recombinant KIT T670I protein that can be used to study KIT T670I-related functions .

HY-E70739

KIT V559D/T670I Recombinant Human Active Protein Kinase	c-Kit	Cancer
KIT (CD117) is an important cell surface marker used to identify certain types of hematopoietic(blood) progenitors in the bone marrow. KIT is a cytokine receptor expressed on the surface of hematopoietic stem cells as well as other cell types. Altered forms of this receptor may be associated with some types of cancer. KIT V559D/T670I is a mutant of KIT. KIT V559D/T670I Recombinant Human Active Protein Kinase is a recombinant KIT V559D/T670I protein that can be used to study KIT V559D/T670I-related functions .

HY-148827A

GEM-231 sodium HYBO-165 sodium	PKA	Cancer
GEM231 sodium is an 18mer antisense oligonucleotide targeting the mRNA of the *PKA-I* (RIα regulatory subunit of cAMP dependent protein kinase type I ). GEM231 sodium induces cell growth arrest, apoptosis, and differentiation in a variety of cancer cell lines in vitro and in tumors in vivo.

HY-148827

GEM-231 HYBO-165	PKA	Cancer
GEM231 is an 18mer antisense oligonucleotide targeting the mRNA of the *PKA-I* (RIα regulatory subunit of cAMP dependent protein kinase type I ). GEM231 induces cell growth arrest, apoptosis, and differentiation in a variety of cancer cell lines in vitro and in tumors in vivo.

HY-131777

2-Cl-cAMP	PKA	Others
2-Cl-cAMP is an analog of cAMP and a potent stimulator of cAMP-dependent protein kinases such as PKA type I and II. 2-Cl-cAMP can be used as starting material for cyclic nucleotides .

HY-114192

TGFβRI-IN-1	TGF-β Receptor	Cancer
TGFβRI-IN-1 is an oral active and selective *TGFβ receptor type* I (TGFβRI)** kinase inhibitor, with IC₅₀ values of 2 nM and 7.6 μM for TGFβRI and TGFβRII, respectively .

HY-E70834

JAK1(JH1) Recombinant Human Active Protein Kinase	JAK	Cancer
JAK1 is a non-receptor tyrosine kinase that plays a critical role in cell signaling via type I/II cytokines and interferons (IFNs). JAK1(JH1) is a kinase domain. JAK1(JH1) Recombinant Human Active Protein Kinase is a recombinant JAK1(JH1) protein that can be used to study JAK1(JH1)-related functions .

HY-174665

Human IFNAR2 mRNA	mRNA	Cancer
Human IFNAR2 mRNA encodes the human interferon alpha and beta receptor subunit 2 (IFNAR2) protein, a protein that belongs to the type II cytokine receptor family. IFNAR2 is a type I membrane protein that forms one of the two chains of a receptor for interferons alpha and beta. Binding and activation of the receptor stimulates Janus protein kinases, which in turn phosphorylate several proteins, including STAT1 and STAT2.

HY-W707119

RepSox hydrochloride E-616452 hydrochloride; SJN 2511 hydrochloride	TGF-beta/Smad Anaplastic lymphoma kinase (ALK)	Metabolic Disease
RepSox hydrochloride is a potent and selective inhibitor of transforming growth factor-β receptor I/activin-like kinase 5 (TGF-β-RI/ALK5). RepSox hydrochloride inhibits ALK5 autophosphorylation with an IC50 value of 4 nM. RepSox hydrochloride can be used in the study of obesity and related metabolic diseases such as type 2 diabetes.

HY-151233

ALK5-IN-10	TGF-β Receptor	Cancer
ALK5-IN-10 (Compound 5d) is a TGF-β type I receptor kinase ALK5 inhibitor, with IC₅₀s of 0.007 and 1.98 μM for ALK5 and p38α, respectively. ALK5-IN-10 can be used for the research of cancer .

HY-137628

Sp-8-PIP cAMP	PKA	Cancer
Sp-8-PIP cAMP sodium is a non-corresponding isomer of 8-Piperidino-cAMP. 8-Piperidino-cAMP binds with high affinity to site A of the regulatory subunit of cAMP-dependent protein kinase type I (AI). Sp-8-PIP cAMP sodium can be used as an antagonist of cAMP-induced activation .

HY-164469

CHMFL-48	Bcr-Abl Apoptosis STAT	Cancer
CHMFL-48 is an orally active BCR-ABL kinase inhibitor targeting both wild-type (wt) and various imatinib-resistant mutants. The IC₅₀ values for CHMFL-48 against ABL wild-type and ABL T315I mutant are 1 nM and 0.8 nM, respectively. CHMFL-48 exerts its effects by blocking the autophosphorylation of BCR-ABL wild-type and mutant forms, which impacts downstream signaling mediators such as STAT5 and CRKL, leading to cell cycle arrest and induction of apoptosis. CHMFL-48 holds potential for research into chronic myeloid leukemia (CML) .

Cat. No.	Product Name

HY-L018

TGF-beta/Smad Compound Library

413 compounds

The transforming growth factor beta (TGF-β) signaling pathway is involved in many cellular processes in both the adult organism and the developing embryo including cell growth, cell differentiation, apoptosis, cellular homeostasis and other cellular functions. The TGF-β superfamily comprises TGF-βs, bone morphogenetic proteins (BMPs), activins and related proteins. Signaling begins with the binding of a TGF beta superfamily ligand to a TGF beta type II receptor. The type II receptor is a serine/threonine receptor kinase, which catalyzes the phosphorylation of the Type I receptor. The type I receptor then phosphorylates receptor-regulated SMADs (R-SMADs) which can now bind the coSMAD (e.g. SMAD4). R-SMAD/coSMAD complexes accumulate in the nucleus where they act as transcription factors and participate in the regulation of target gene expression. Deregulation of TGF-β signaling contributes to developmental defects and human diseases, including cancers, some bone diseases, chronic kidney disease, etc.

MCE designs a unique collection of 413 TGF-beta/Smad signaling pathway compounds. TGF-beta/Smad Compound Library acts as a useful tool for TGF-beta/Smad-related drug screening and disease research.

Cat. No.	Product Name	Target	Research Area

HY-P0221

PACAP (1-38), human, ovine, rat 5 Publications Verification Pituitary Adenylate Cyclase Activating Polypeptide 38	PACAP Receptor ERK EGFR Reactive Oxygen Species (ROS) Calcium Channel	Infection Neurological Disease
PACAP (1-38), human, ovine, rat is a PAC₁ receptor agonist. PACAP (1-38), human, ovine, rat binds to PACAP type I receptor, PACAP type II receptor VIP1, and PACAP type II receptor VIP2 with IC₅₀s of 4 nM, 2 nM, and 1 nM, respectively. PACAP (1-38), human, ovine, rat increases the α-secretase activity. PACAP (1-38), human, ovine, rat elevates cytosolic Ca ²⁺, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP (1-38), human, ovine, rat demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP (1-38), human, ovine, rat can be used for neurotrophic and neuroprotective research .

HY-P10954

Link N peptide	p38 MAPK	Others
Link N peptide is a proteoglycan aggregates activator in the extracellular matrix. Link N peptide can selectively activate the p38 mitogen-activated protein kinase (MAPK) pathway to promote the expression of type I and II collagens in human intervertebral disc cells. Link N peptide is promising for research of intervertebral disc degeneration-related diseases .

HY-P0221A

PACAP (1-38), human, ovine, rat TFA Pituitary Adenylate Cyclase Activating Polypeptide 38 TFA	PACAP Receptor ERK EGFR Reactive Oxygen Species (ROS) Calcium Channel	Neurological Disease
PACAP (1-38), human, ovine, rat TFA is a PAC₁ receptor agonist. PACAP (1-38), human, ovine, rat TFA binds to PACAP type I receptor, PACAP type II receptor VIP1, and PACAP type II receptor VIP2 with IC₅₀s of 4 nM, 2 nM, and 1 nM, respectively. PACAP (1-38), human, ovine, rat TFA increases the α-secretase activity. PACAP (1-38), human, ovine, rat TFA elevates cytosolic Ca ²⁺, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP (1-38), human, ovine, rat TFA demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP (1-38), human, ovine, rat TFA can be used for neurotrophic and neuroprotective research .

Cat. No.	Product Name	Target	Research Area	Image

HY-P992326

BOT1711	PDGFR	Inflammation/Immunology Cancer
BOT1711 is a human IgG1κ monoclonal antibody targeting PDGFRB/CD140b. PDGFRB/CD140b belongs to type I receptor tyrosine kinases (RTKs), and is mainly expressed in vascular smooth muscle cells, pericytes, fibroblasts, certain mesenchymal stem cells, and tumor stromal cells.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N4119

Neoeriocitrin	Structural Classification Flavonoids other families Flavonones Phenols Polyphenols Plants Source Classification	Phosphatase Cholinesterase (ChE) p38 MAPK Apoptosis Autophagy
Neoeriocitrin is a Naringin (HY-N0153) analogue found in Drynaria Rhizome. Neoeriocitrin induces cells proliferation, differentiation, up-regulates type I collagen, osteocalcin, and key osteogenic markers, and increases ALP activity. Neoeriocitrin increases expression of Runx2, COL I, OCN and Beclin1. Neoeriocitrin inhibits phosphorylation of P38 mitogen-activated protein kinase, reduces acetylcholinesterase (AChE) activity, and increases choline acetyltransferase (ChAT) activity. Neoeriocitrin reduces apoptosis and induces autophagy. Neoeriocitrin can be used for the researches of osteoporosis and Alzheimer's disease .

HY-N4119R

Neoeriocitrin (Standard)	Structural Classification Flavonoids other families Flavonones Phenols Polyphenols Plants Source Classification	Reference Standards Phosphatase Cholinesterase (ChE) p38 MAPK Apoptosis Autophagy
Neoeriocitrin (Standard) is the analytical standard of Neoeriocitrin (HY-N4119). This product is intended for research and analytical applications. Neoeriocitrin is a Naringin (HY-N0153) analogue found in Drynaria Rhizome. Neoeriocitrin induces cells proliferation, differentiation, up-regulates type I collagen, osteocalcin, and key osteogenic markers, and increases ALP activity. Neoeriocitrin increases expression of Runx2, COL I, OCN and Beclin1. Neoeriocitrin inhibits phosphorylation of P38 mitogen-activated protein kinase, reduces acetylcholinesterase (AChE) activity, and increases choline acetyltransferase (ChAT) activity. Neoeriocitrin reduces apoptosis and induces autophagy. Neoeriocitrin can be used for the researches of osteoporosis and Alzheimer's disease .

Species:	Human (6) Mouse (1)
Tag:	His (5) Tag Free (1) GST (3)
Source:	HEK293 (1) Sf9 insect cells (5) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P705662

	CAMKI alpha/CAMK1 Protein, Human (Active) rHuCAMK1, His; Calcium/Calmodulin-Dependent Protein kinase Type 1; CaM kinase I; CaMKI-Alpha; CAMK1	Human	E. coli
	CAMKI alpha/CAMK1 Protein, Human, a recombinant human CAMK1 produced in HEK293 cells. CAMK1 is involved in multiple cell functions, including calmodulin binding, ATP binding, signal transduction, development and cell differentiation.

HY-P702654

	CAMK1 alpha/CAMK1 Protein, Human (Active, sf9, His, GST) CAMK1; calcium/calmodulin-dependent protein kinase I; calcium/calmodulin-dependent protein kinase Type 1; CaMKI; caM-KI; caMKI-alpha; caM kinase I alpha; CAMKI; MGC120317; MGC120318;	Human	Sf9 insect cells
	CAMK1 alpha/CAMK1 Protein, Human (sf9, His, GST) is the recombinant human-derived CAMK1 alpha, expressed by Sf9 insect cells , with His, GST labeled tag.

HY-P7714

	CAMKI alpha/CAMK1 Protein, Human (Active, HEK293, His) rHuCAMK1, His; Calcium/Calmodulin-Dependent Protein kinase Type 1; CaM kinase I; CaMKI-Alpha; CAMK1	Human	HEK293
	CAMKI alpha/CAMK1 Protein, Human (HEK293, His), a recombinant human CAMK1 produced in HEK293 cells, has a His tag at the N-terminus. CAMK1 is involved in multiple cell functions, including calmodulin binding, ATP binding, signal transduction, development and cell differentiation.

HY-P702653

	CAMK1 delta Protein, Human (Active, sf9, GST) Calcium/calmodulin-dependent protein kinase Type 1D; CaM kinase I delta; CaM kinase ID; CaM-KI delta; CaMKI delta; CaMKID	Human	Sf9 insect cells
	CAMK1 delta Protein, Human (sf9, GST) is the recombinant human-derived CAMK1 delta, expressed by Sf9 insect cells , with GST labeled tag.

HY-P702980

	PRKAR1B Protein, Human (sf9, His) cAMP-dependent protein kinase Type I-beta regulatory subunit; PRKAR1B	Human	Sf9 insect cells
	PRKAR1B Protein, Human (sf9, His) is the recombinant human-derived PRKAR1B, expressed by Sf9 insect cells , with His labeled tag. ,

HY-P701757

	PNCK Protein, Human (Active, sf9, His, GST) PNCK; Calcium/calmodulin-dependent protein kinase Type 1B; CaM kinase I beta; CaM kinase IB; CaM-KI beta; CaMKI-beta; Pregnancy up-regulated non-ubiquitously-expressed CaM kinase	Human	Sf9 insect cells
	The PNCK protein is a calcium/calmodulin-dependent protein kinase and a key component of the calcium-triggered signaling cascade. In vitro, PNCK exhibits the ability to phosphorylate CREB1 and SYN1/synapsin I, emphasizing its involvement in regulating cellular processes associated with these substrates. PNCK Protein, Human (sf9, His, GST) is the recombinant human-derived PNCK protein, expressed by sf9 insect cells , with N-8*His, N-GST labeled tag.

HY-P75982

	PRKAR1A Protein, Mouse (sf9, His) cAMP-dependent protein kinase Type I-alpha regulatory subunit; Tissue-specific extinguisher 1; TSE1; PKR1; PRKAR1	Mouse	Sf9 insect cells
	PRKAR1A protein is a regulatory subunit of cAMP-dependent protein kinase that mediates cellular responses to cAMP signaling.The inactive holoenzyme has two regulatory chains and two catalytic chains.PRKAR1A Protein, Mouse (sf9, His) is the recombinant mouse-derived PRKAR1A protein, expressed by Sf9 insect cells , with C-His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-117287

Deucravacitinib

30+ Cited Publications

Deucravacitinib (BMS-986165) is an orally active allosteric inhibitor of tyrosine kinase 2 (TYK2), with an IC₅₀ of 0.2 nM and a K_i of 0.02 nM against the JH2 domain of TYK2, and it exhibits selectivity over other JAK subtypes and most of the kinome. Deucravacitinib blocks IL-23, IL-12, p-STAT1/3 and Type I IFN signaling, and inhibits Th17/Th1-mediated psoriasis inflammation . Deucravacitinib can be used in research related to moderate-to-severe plaque psoriasis, inflammatory bowel disease and systemic lupus erythematosus .

HY-153701S

Envudeucitinibum

Envudeucitinibum (Envudeucitinib) is a highly selective, allosteric and orally active TYK2 inhibitor binding to the JH2 domain of TYK2. Envudeucitinibum has no off-target effects on other kinases (JAK1-3). Envudeucitinibum reduces signaling and production of proinflammatory cytokines including IL-12, IL-23, IL-17, and type I interferons (IFNs). Envudeucitinibum can be used for the research of plaque psoriasis, systemic lupus erythematosus (SLE), and other immune-mediated diseases .

HY-13012S

RepSox-d5
RepSox-d₅ (E-616452-d₅) is the deuterium labeled RepSox (HY-13012). RepSox (E-616452) is a potent and selective transforming growth factor-beta receptor I/activin like kinase 5 (TGF-β-RI/ALK5) inhibitor. RepSox inhibits ALK5 autophosphorylation with an IC₅₀ value of 4 nM. RepSox can be used for the research of obesity and associated metabolic diseases such as type 2 diabetes .

Host:	Rabbit (4)
Reactivity:	Human (4) Rat (3) Mouse (1)
Application:	WB (4)
Isotype:	IgG (4)
Conjugation:	Non-conjugated (4)
Clonality:	Monoclonal (3) Recombinant (3)
Modification:	Unmodified (3)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P82712

	ALK-1 Antibody (YA2457) ACVRL1; ACVRLK1; ALK1; Serine/threonine-protein kinase receptor R3; SKR3; Activin receptor-like kinase 1; ALK-1; TGF-B superfamily receptor Type I; TSR-I	WB	Human, Mouse, Rat
	ALK-1 Antibody (YA2457) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ALK-1.

HY-P87011

	PIP5K1C Antibody (YA6704) Diphosphoinositide kinase antibody; LCCS3 antibody; Phosphatidylinositol-4-phosphate 5-kinase Type I gamma antibody; Phosphatidylinositol-4-phosphate 5-kinase Type-1 gamma antibody; PI51C antibody; PI51C_HUMAN antibody; PIP5K GAMMA antibody; PIP5K1-gamma antibody; Pip5k1c antibody; PIP5KIgamma antibody; Diphosphoinositide kinase antibody; LCCS3 antibody; Phosphatidylinositol-4-phosphate 5-kinase Type I gamma antibody; Phosphatidylinositol-4-phosphate 5-kinase Type-1 gamma antibody; PI51C antibody; PI51C_HUMAN antibody; PIP5K GAMMA antibody; PIP5K1-gamma antibody; Pip5k1c antibody; PIP5KIgamma antibody; PtdIns(4)P 5 kinase gamma antibody; PtdIns(4)P-5-kinase 1 gamma antibody; Type I P; IP : kinase antibody;	WB	Human
	PIP5K1C Antibody (YA6704) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PIP5K1C.

HY-P82006

	PKA RI alpha Antibody (YA1751) PRKAR1A; PKR1; PRKAR1; TSE1; cAMP-dependent protein kinase Type I-alpha regulatory subunit; Tissue-specific extinguisher 1; TSE1	WB	Human, Rat
	PKA RI alpha Antibody (YA1751) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PKA RI alpha.

HY-P82006A

	PKA RI alpha Antibody (YA1751)(PBS only) PRKAR1A; PKR1; PRKAR1; TSE1; cAMP-dependent protein kinase Type I-alpha regulatory subunit; Tissue-specific extinguisher 1; TSE1	WB	Human, Rat
	PKA RI alpha Antibody (YA1751) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PKA RI alpha.